Tetrahydrobiopterin prevents cyclosporine-induced vasomotor dysfunction

Transplantation

Volumn 79, Issue 8, 2005, Pages 876-881

  Ramzy, Danny ^a,b   Rao, Vivek ^a,b   Tumiati, Laura C ^a,b   Xu, Ning ^a,b   Miriuka, Santiago ^a,c   Delgado, Diego ^a,c   Ross, Heather J ^a,c  

^a TORONTO GENERAL HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Cyclosporine; Endothelial dysfunction; Endothelin 1; Nitric oxide; Tetrahydrobiopterin

Indexed keywords

ACETYLCHOLINE; CYCLOSPORIN A; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; NITRIC OXIDE; NITROPRUSSIDE SODIUM; SODIUM CHLORIDE; TETRAHYDROBIOPTERIN;

ANIMAL MODEL; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM INJURY; MALE; MYOGRAPHY; NONHUMAN; PRIORITY JOURNAL; RAT; THORACIC AORTA; TRANSPLANTATION; VASOMOTOR DISORDER; VASOSPASM;

ANIMALS; BIOPTERIN; CYCLOSPORINE; ENDOTHELIAL CELLS; ENDOTHELIN-1; MALE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; RATS; RATS, INBRED LEW; RECEPTORS, ENDOTHELIN; VASODILATION;

EID: 17844386104     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000157364.80712.45     Document Type: Article

References (45)

1. Kaham BD. Cyclosporine. N Eng J Med 1989; 321: 1725.
2. Paul LC. Overview of side effects of immunosuppressive therapy. Transpl Proc 2001; 33: 2089.
3. Billingham ME. Cardiac transplant atherosclerosis. Transpl Proc 1987; 19: 19.
4. Calne RY, Collier DSJ, Lim S, et al. Rapamycin for immunosuppression in organ allografting. Lancet 1989; 8656: 227.
5. Meiser BM, Billingham ME, Morris RE. Effects of cyclosporin, FK506, and rapamycin on graft-vessel disease. Lancet 1991; 339: 1297.
6. Zoja C, Furci L, Ghilardi F, et al. Cyclosporine-induced endothelial cell injury. Lab Invest 1986; 55: 455.
7. Paul LC. Endothelial dysfunction, atherosclerosis and cyclosporine in renal transplantation. Nether J Med 2001; 59: 1.
8. Buetler TM, Cottet-Marie F, Krauskopf A, et al. Does cyclosporine A generate free radicals? TiPS 2000; 21: 288.
9. Morris ST, McMurray JJ, Rodger SC, et al. Endothelial dysfunction in renal transplant recipients maintained with cyclosporine. Kidney Int 2000; 57: 1100.
10. Schrama YC, Dam T, Fijnheer R, et al. Cyclosporine is associated with endothelial dysfunction but not with platelet activation in renal transplantation. Nether J Med 2001; 59: 6.
11. Lau DCW, Wong K-L, Hwang WS. Cyclosporine toxicity on cultured rat microvascular endothelial cells. Kidney Int 1989; 35: 604.
12. Drueke TB, Abdulmassih Z, Lacour B, et al. Atherosclerosis and lipid disorders after renal transplantation. Kidney Int 1991; 39: S24.
13. Kronenberg F, Konig P, Lhotta K, et al. Cyclosporin and serum lipids in renal transplant recipients. Lancet 1993; 341: 765.
14. Diederich D, Yang Z, Luscher TF. Chronic cyclosporine therapy impairs endothelium-dependent relaxation in the renal artery of the rat. J Am Soc Nephrol 1992; 2: 1291.
15. Bossaller C, Porstermann U, Hertel R, et al. Cyclosporin A inhibits endothelium-dependent vasodilation and vascular prostacyclin production. Eur J Pharmacol 1989; 165: 165.
16. Sudhir K, MacGregor JS, DeMarco T, et al. Cyclosporine impairs release of endothelium-derived relaxing factors in epicardial and resistance coronary arteries. Circulation 1994; 90: 3018.
17. Abraham JS, Bentley FR, Garrison RN. The role of intrarenal prostaglandins and angiotensin-II in acute cyclosporine-induced vasoconstriction. Surgery 1991; 110: 343.
18. Morgan BJ, Lyson T, Sherrer U, et al. Cyclosporine causes sympathetically mediated elevations in arterial pressure in rats. Hypertension 1991; 18: 458.
19. Kon V, Sugiura M, Inagami T, et al. Role of endothelin in cyclosporine-induced glomerular dysfunction. Kidney Int 1990; 37: 1487.
20. Bunchaman TE, Brookshire CA. Cyclosporine stimulated synthesis of Endothelin by human endothelial cells in tissue culture. Kidney Int 1990; 37: 365A.
21. Carrier M, Tronc F, Stewart D, et al. Dose-dependent effect of cyclosporine on renal arterial resistance in dogs. Am J Physiol 1991; 261: H1791.
22. Takeda Y, Itoh Y, Yoneda T, et al. Cyclosporine A induces endothelin-1 release from cultured rat vascular smooth muscle cells. Eur J Pharmacol 1993; 233: 299.
23. Stroes ESG, Luscher TF, de Groot FG, et al. Cyclosporine A increases nitric oxide activity in vivo. Hypertension 1997; 29: 570.
24. Abassi ZA, Pieruzzi F, Nakhoul F, et al. Effects of cyclosporin A on the synthesis, excretion, and metabolism of Endothelin in the rat. Hypertension 1996; 27: 1140.
25. Edwards BS, Hunt SA, Fowler MB, et al. Effects of cyclosporine on plasma Endothelin levels in humans after cardiac transplantation. Am J Cardiol 199l; 67: 782.
26. Forslund T, Hannonen P, Reitamo S, et al. Hypertension in cyclosporine A-treated patients is independent of circulating Endothelin levels. J Intern Med 1995; 238: 71.
27. Calo L, Semplicini A, Davis PA, et al. Cyclosporin-induced endothelial dysfunction and hypertension: are nitric oxide system abnormality and oxidative stress involved. Transpl Int 2000; 13(Suppl 1): S413.
28. Diederich D, Skopec J, Diederich A, et al. Cyclosporine produces endothelial dysfunction by increasing production of superoxide. Hypertension 1994; 23(part 2): 957.
29. Cosentino F, Luscher TF. Tetrahydrobiopterin and endothelial nitric oxide synthase activity. Cardiovasc Res 1999; 43: 274.
30. Vazquez-Vivar J, Kalyanaraman B, Martasek P, et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci USA 1998; 95: 9220.
31. Tiefenbacher CP. Tetrahydrobiopterin: a critical cofactor for eNOS and a strategy in treatment of endothelial dysfunction? Am J Physiol Heart Circ Physiol 2001; 280: H2484.
32. Tiefenbacher CP, Bleeke T, Vahl C, et al. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation 2000; 102: 2172.
33. Maier W, Cosentino F, Lutolf RB, et al. Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharm 2000; 35: 173.
34. Verma S, Maitland A, Weisel RD, et al. Novel cardioprotective effects of tetrahydrobiopterin after anoxia and reoxygenation: identifying cellular targets for pharmacologic manipulation. J Thorac Cardiovasc Surg 2002; 123(6): 1074.
35. Setoguchi S, Mohri M, Shimokawa H, et al. Tetrahydrobiopterin improves endothelial dysfunction in coronary microcirculation in patients without epicardial coronary artery disease. J Am Coll Cardiol 2001; 38: 493.
36. Heitzer T, Krohn K, Albers S, et al. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with Type II diabetes mellitus. Diabetologia 2000; 43: 1435.
37. Heitzer T, Brockhoff C, Mayer B, et al. Tetrahydrobiopterin improves endothelial-dependent vasodilation in chronic smokers: evidence for a dysfunctional nitric oxide synthase. Circ Res 2000; 86: E36.
38. Mehlhorn U, Krahwinkel A, Geissler HJ, et al. Nitrotyrosine and 8-isoprostane formation indicate free radical-mediated injury in hearts of patients subjected to cardioplegia. J Thorac Cardiovasc Surg 2003; 125: 178.
39. Waugh RJ, Morrow JD, Roberts LJ, et al. Identification and relative quantitation of F2-isoprostane regioisomers formed in vivo in the rat. Free Radic Biol Med 1997; 23: 943.
40. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248.
41. Hillinger S, Sandera P, Carboni GL, et al. Survival and graft function in a large animal lung transplant model after 30 h preservation and substitution of the nitric oxide pathway. Eur J Cardio Thorac Surg 2001; 20: 508.
42. Schmid RA, Hillinger S, Walter R, et al. The nitric oxide synthase co-factor tetrahydrobiopterin reduces allograft ischemia-reperfusion injury after transplantation. J Thorac Cardiovasc Surg 1999; 118: 726.
43. Malo O, Desjardins F, Tanguay J-F, et al. Tetrahydrobioterin and antioxidants reverse the coronary endothelial dysfunction associated with left ventricular hypertrophy in a porcine model. Cardiovasc Res 2003; 59: 501.
44. Fukuda Y, Teragawa H, Matsuda K, et al. Tetrahydrobiopterin restores endothelial function of coronary arteries in patients with hypercholesterolemia. Heart 2002; 87: 264.
45. Ihlemann N, Rask-Madsen C, Perner A, et al. Tetrahydrobiopterin restores endothelial dysfunction induced by an oral glucose challenge in healthy subjects. Am J Physiol Heart Circ Physiol 2003; 285: H875.